A EAACI drug allergy interest group survey on how European allergy specialists deal with β-lactam allergy.
Adult
Allergists
/ psychology
Anti-Bacterial Agents
/ immunology
Child
Drug Hypersensitivity
/ blood
Europe
Female
Gram-Positive Bacterial Infections
/ drug therapy
Humans
Immunoglobulin E
/ blood
Macrolides
/ therapeutic use
Male
Nasal Provocation Tests
Quinolones
/ therapeutic use
Skin Tests
Surveys and Questionnaires
beta-Lactams
/ immunology
Europe
allergy
diagnosis
guidelines
β-Lactam
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
02
04
2018
revised:
09
07
2018
accepted:
22
08
2018
pubmed:
15
1
2019
medline:
9
6
2020
entrez:
15
1
2019
Statut:
ppublish
Résumé
An accurate diagnosis of β-lactam (BL) allergy can reduce patient morbidity and mortality. Our aim was to investigate the availability of BL reagents, their use and test procedures in different parts of Europe, as well as any differences in the diagnostic workups for evaluating subjects with BL hypersensitivity. A survey was emailed to all members of the EAACI Drug Allergy Interest Group (DAIG) between February and April 2016, and the questionnaire was meant to study the management of suspected BL hypersensitivity. The questionnaire was emailed to 82 DAIG centres and answered by 57. Amoxicillin alone or combined to clavulanic acid were the most commonly involved BL except in the Danish centre, where penicillin V was the most frequently suspected BL. All centres performed an allergy workup in subjects with histories of hypersensitivity to BL: 53 centres (93%) followed DAIG guidelines, two national guidelines and two local guidelines. However, there were deviations from DAIG recommendations concerning allergy tests, especially drug provocation tests. A significant heterogeneity exists in current practice not only among countries, but also among centres within the same country. This suggests the need to re-evaluate, update and standardize protocols on the management of patients with suspected BL allergy.
Substances chimiques
Anti-Bacterial Agents
0
Macrolides
0
Quinolones
0
beta-Lactams
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1052-1062Subventions
Organisme : European Regional Development Fund (ERDF)
ID : ARADyAL RD16/0006/0001
Pays : International
Organisme : European Regional Development Fund (ERDF)
ID : PI15/01206
Pays : International
Organisme : European Regional Development Fund (ERDF)
ID : RIRAAF RD12/0013/0001
Pays : International
Informations de copyright
© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.